Global

Lung Cancer May Be Entering the Chemo-Replacement Fight

A Blood Test Can See Risk. Policy Cannot Yet Hold It.

AI can flag hidden cardiac risk. The dangerous part is what health systems do next

Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence

Down Syndrome Cannot Stay Outside Alzheimer’s Trials

More Children Got A First Vaccine. Millions Still Fell Out Of The System.

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.

Tau Is Back. Certainty Is Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
